WHAT WE DO
AT MEDSIR WE ARE DEDICATED TO OFFER THE MOST RELEVANT NEWS ON THE LATEST ADVANCEMENTS IN ONCOLOGY CLINICAL RESEARCH. FIND OUT THE LATEST NEWS ON ONCOLOGY RESEARCH, REGULATORY APPROVALS, EVENTS, SCIENTIFIC CONFERENCES AND MUCH MORE!
The I3LUNG website is live!
Spotlight - ORPHEUS Penile carcinoma trial
What is immunotherapy?
The Microbiome and Cancer
Joining forces with Dana-Farber Cancer Institute to investigate the role of microbiome
Toripalimab joins the list of ICIs that improve efficacy when added to chemotherapy in 1L NSCLC
Pembrolizumab may be the new standard of care for RCC with intermediate to high risk of recurrence
Ipilimumab-nivolumab combo as 2L does not improve survival for immunotherapy naive NSCLC
COPERNICO Results at ERS: immunotherapy combo reduces hospitalization for COVID-19 pneumonia